Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Giant cell tumour of bone in the denosumab era.

European journal of cancer (Oxford, England : 1990) - 1 May 2017

van der Heijden Lizz, Dijkstra P D Sander, Blay Jean-Yves, Gelderblom Hans

Abstract excerpt

Giant cell tumour of bone (GCTB) is an intermediate locally aggressive primary bone tumour, occurring mostly at the meta-epiphysis of long bones. Overexpression of receptor activator of nuclear factor kappa-B ligand (RANKL) by mononuclear neoplastic stromal cells promotes recruitment of numerous reactive multinucleated osteoclast-like giant cells, causing lacunar bone resorption. Preferential treatment is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bone Density Conservation Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Clinical Trials, Phase II as Topic

Share to Combined Modality Therapy

Share to Genes, Neoplasm

Share to Mutation

Share to Postoperative Complications

Source

Identifiers

PMID: 28365529
DOI: 10.1016/j.ejca.2017.02.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Giant cell tumour of bone in the denosumab era.PMID 28365529Read ↗

Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.Semantic proximity Read ↗

Giant cell tumor of bone: updated molecular pathogenesis and tumor biology.Semantic proximity Read ↗

Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.Semantic proximity Read ↗

Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.Semantic proximity Read ↗

H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases.Semantic proximity Read ↗

Significance of EGFR/HER2 Expression and PIK3CA Mutations in Giant Cell Tumour of Bone DevelopmentSemantic proximity Read ↗

Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.Semantic proximity Read ↗

Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.Semantic proximity Read ↗

Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of boneSemantic proximity Read ↗

Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.Semantic proximity Read ↗

Epigenetic lockdown of CDKN1A (p21) and CDKN2A (p16) characterises the neoplastic spindle cell component of giant cell tumours of bone.Semantic proximity Read ↗

Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.